Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 129
- Type
- D - Journal article
- DOI
-
10.1038/bjc.2017.75
- Title of journal
- Br J Cancer
- Article number
- -
- First page
- 1166
- Volume
- 116
- Issue
- 9
- ISSN
- 1532-1827
- Open access status
- Compliant
- Month of publication
- March
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
https://www.nature.com/articles/bjc201775#Sec17
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
21
- Research group(s)
-
-
- Citation count
- 14
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
